Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Age-Related Macular Degeneration

In brief

This study will compare the safety and efficacy of Medidur FA treatment in one eye to the sham-treated fellow eye of subjects with geographic atrophy secondary to AMD.

Key facts

Study ID

NCT00695318

Run by

Alimera Sciences

People needed

17

Starts

2008-12-01

Last updated by the study team

2015-05-29

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis bilateral GA secondary to AMD of ≥ 0.5 and ≤ 7 MPS disc areas
• Males and non-pregnant females 55 years old or older

You may not qualify if…

• GA secondary to any condition other than AMD in either eye
• History of or current CNV in either eye or the need for anti-angiogenic therapy
• Glaucoma or ocular hypertension (IOP > 21 mmHg OR concurrent therapy at screening with IOP-lowering agents) in either eye
• Treatment with intravitreal, subtenon, or periocular steroid within 6 months prior to enrollment in either eye
• Any change in systemic steroid therapy within 3 months of screening
• History of vitrectomy in either eye
• Any ocular surgery within 12 weeks of screening in either eye

Where it is running

• Kresge Eye Institute — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.